Resource Tracking
AVAC serves as the secretariat for the HIV
Vaccines and Microbicides
Resource Tracking Working Group, which also
includes the International AIDS Vaccine
Initiative, IPM, the International Partnership
for Microbicides and
UNAIDS. This year's new report along with
archives of the Working Group's
previous reports can be found at www.hivresourcetracking.org.
The HIV Vaccines and Microbicides Resource Tracking Working Group
Report 2010
Advancing the Science in a Time of Fiscal Constraint: Funding for HIV Prevention Technologies in 2009.
The report finds stability in funding for HIV prevention research from 2008 to 2009. HIV vaccines continued to receive the majority of funding, with a total of US$868 million, which was equal to 2008 funding levels. Investment in microbicides was US$236 million, a decline of 3 percent from 2008 levels. Funding for PrEP increased by 18 percent over 2008 levels to US$52 million.
The stability in funding is encouraging, given a 10 percent decrease in funding for AIDS vaccine research seen in 2008, but the Working Group identified several areas of concern if funding remains flat, including escalating costs of late-stage clinical research, dependency on a small group of funders and a lack of diversity in funders.
The HIV Vaccines and Microbicides Resource Tracking Working Group
Report 2010
Advancing the Science in a Time of Fiscal Constraint: Funding for HIV Prevention Technologies in 2009.
The report finds stability in funding for HIV prevention research from 2008 to 2009. HIV vaccines continued to receive the majority of funding, with a total of US$868 million, which was equal to 2008 funding levels. Investment in microbicides was US$236 million, a decline of 3 percent from 2008 levels. Funding for PrEP increased by 18 percent over 2008 levels to US$52 million.
The stability in funding is encouraging, given a 10 percent decrease in funding for AIDS vaccine research seen in 2008, but the Working Group identified several areas of concern if funding remains flat, including escalating costs of late-stage clinical research, dependency on a small group of funders and a lack of diversity in funders.